Despite the plethora of empirical studies conducted to date, debate continues about whether
and to what extent results should be returned to participants of genomic research. We aimed …

Disclaimer: This statement is designed primarily as an educational resource for medical
geneticists and other clinicians to help them provide quality medical services. Adherence to …

If genome sequencing is performed in health care, in theory the opportunity arises to take a
further look at the data: opportunistic genomic screening (OGS). The European Society of …

ABSTRACT Purpose Secondary findings (SFs) are present in 1–4% of individuals
undergoing genome/exome sequencing. A review of how SFs are disclosed and what …

Results Using this workflow, we attempted to recontact a diverse pilot cohort of 104
nephrology research participants with actionable genetic findings, encompassing 34 …

Genome‐wide (exome or genome) sequencing (GWS) has the potential to detect incidental
findings (IFs): variants unrelated to the primary indication for testing that may be of medical …

Simple Summary Next-generation sequencing (NGS)-based assay is widely used in clinical
practice due to its reimbursement by Japan's universal health-care system for cancer …

Exome sequencing (ES) has revolutionized diagnostic procedures in medical genetics,
particularly for developmental diseases. The variety and complexity of the information …

Increasing use of diagnostic genomic sequencing is pushing health services to confront the
issue of opportunistic genomic screening (OGS). To date, OGS has been offered …

Purpose Patients undergoing clinical exome sequencing (ES) are routinely offered the
option to receive secondary findings (SF). However, little is known about the views of …